Advertisement
Canada markets closed

  • S&P/TSX

    22,011.72
    +139.76 (+0.64%)
     

  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     

  • DOW

    38,503.69
    +263.71 (+0.69%)
     

  • CAD/USD

    0.7321
    +0.0001 (+0.01%)
     

  • CRUDE OIL

    83.34
    -0.02 (-0.02%)
     

  • Bitcoin CAD

    90,951.30
    -87.43 (-0.10%)
     

  • CMC Crypto 200

    1,433.51
    +18.75 (+1.33%)
     

  • GOLD FUTURES

    2,333.90
    -8.20 (-0.35%)
     

  • RUSSELL 2000

    2,002.64
    +35.17 (+1.79%)
     

  • 10-Yr Bond

    4.5980
    -0.0250 (-0.54%)
     

  • NASDAQ futures

    17,733.25
    +126.50 (+0.72%)
     

  • VOLATILITY

    15.69
    -1.25 (-7.38%)
     

  • FTSE

    8,044.81
    +20.94 (+0.26%)
     

  • NIKKEI 225

    38,329.39
    +777.23 (+2.07%)
     

  • CAD/EUR

    0.6833
    -0.0003 (-0.04%)
     

Stocks in play: Emerald Health Therapeutics, Inc.

Baystreet.ca

Has entered into a binding term sheet with certain institutional accredited investors under which the Investors have agreed, subject to certain customary conditions, to purchase 10,344,827 units of Emerald at a price of $0.29 per Unit for total gross proceeds of $3,000,000. These Units will represent the remainder of the financing previously announced on December 16, 2019, however the securities to be issued under the Offering will be offered by way of a shelf prospectus supplement to be filed in all of the provinces of Canada pursuant to National Instrument 44-102 – Shelf Distributions and will not be subject to a hold period. Emerald Health Therapeutics, Inc. shares V.EMH are trading unchanged at $0.31.

Read: Psilocybin Mushrooms Becoming One of the Hottest Investment Stories of 2020